Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
By MICHELLE CHAPMAN, AP Business Writer
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform.
Related Articles
-
Where things stand after another weekend of war -
Ohio State University’s president resigns after reporting ‘inappropriate relationship’ -
Uber’s women-only option goes nationwide in the US -
Travelers encounter long waits at some airports as DHS shutdown affects security checkpoints -
Complaint says men who brought explosives to NYC protest said they were inspired by Islamic State
Early last month Hims & Hers said that it was going to launch a cheaper, off-brand version of the weight-loss pill Wegovy, just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation of the blockbuster medication. At the time, Novo Nordisk vowed to sue Hims, calling the new product “an unapproved, inauthentic, and untested knockoff” of semaglutide, the chemical name for Wegovy.